Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness

Camilo Pena, Leonardo Mirandola, Jose A. Figueroa, Nattamol Hosiriluck, Natallia Suvorava, Kayley Trotter, Adair Reidy, Rahman Rakhshanda, Drew Payne, Marjorie Jenkins, Fabio Grizzi, Lauren Littlefield, Maurizio Chiriva-Internati, Everardo Cobos

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Galectins are family of galactose-binding proteins known to play critical roles in inflammation and neoplastic progression. Galectins facilitate the growth and survival of neoplastic cells by regulating their cross-talk with the extracellular microenvironment and hampering anti-neoplastic immunity. Here, we review the role of galectins in the biology of hematological malignancies and their promise as potential therapeutic agents in these diseases.

Original languageEnglish (US)
Article number87
JournalAnnals of Translational Medicine
Volume2
Issue number9
DOIs
StatePublished - Sep 2014

Keywords

  • Galectin-3 (Gal-3)
  • Galectins
  • Leukemia
  • Lymphomas
  • Multiple myeloma (MM)

Fingerprint Dive into the research topics of 'Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness'. Together they form a unique fingerprint.

  • Cite this

    Pena, C., Mirandola, L., Figueroa, J. A., Hosiriluck, N., Suvorava, N., Trotter, K., Reidy, A., Rakhshanda, R., Payne, D., Jenkins, M., Grizzi, F., Littlefield, L., Chiriva-Internati, M., & Cobos, E. (2014). Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness. Annals of Translational Medicine, 2(9), [87]. https://doi.org/10.3978/j.issn.2305-5839.2014.09.14